VETOQUINOL Corporate brochure 2012 (year 2011)

08 KEY FIGURES & STOCK MARKET DATA 2011 key figures The Group’s business held up strongly last year in the face of contrasting market conditions. With a strong financial structure, Vétoquinol is actively pursuing its investment program in the areas of Research & Development, marketing and manufacturing equipment, the drivers of its organic and external growth. SALES € millions Group business held up strongly due to solid performances in Asia Pacific and the Americas, the acquisition of the Brazilian subsidiary in June 2011 and promising starts for the new products launched over the past 12 months, mainly in Europe. SHAREHOLDERS’ EQUITY € millions Shareholders’ equity is growing strongly, due to healthy net income and the conversion of the B tranche of bonds in February 2011 NET INCOME € millions Net income Group share totaled € 22.7 million, up 2%. This development is explained by: - stable operating income (EBIT), influenced by the arrival of Marbocyl ® generics on the market, tight cost control and the inclusion of a non-recurring indemnity; - a rapidly improving financial result – positive cash flow, no further need to fund non-conversion premiums after February 2011; - an increase in the tax charge. NET CASH ON HAND € millions Group net cash on hand is positive and amounted to € 25.2 million at December 31, 2011 (versus € 7 million at December 31, 2010), after allowing for the impact of the Brazil acquisition. The Group has the financial means to continue its strategy of hybrid growth. 61% Europe 27% Americas 12% Asia Pacific -7.0 2010 - 25.2 2011 22.7 2011 22.3 2010 184.2 2010 211.3 2011 284.1 2011 282.0 2010